The Advocate picks up on the foetal dex story; two issues not covered

The Advocate, in the US, has picked up on the story of how foetal dexamethasone is being used to prevent homosexuality and virilisation in CAH women.

A new report details the dangerous experiementation that’s been going on in fetal engineering, in which doctors are using a synthetic steroid off-label to prevent lesbian, bisexual, intersex, and tomboy babies…

According to the researchers, pregnant women who are at risk for having a child born with the condition congenital adrenal hyperplasia (CAH), an endocrinological condition that can result in female fetuses being born with intersex or more male-typical genitals and brains, are being given dexamethasone, a synthetic steroid, off-label starting as early as week five of the first trimester to try to “normalize” the development of those fetuses, which are female and CAH-affected. Because the drug must be administered before doctors can know if the fetus is female or CAH-affected, only one in eight of those exposed are the target type of fetus.

We draw our readers’ attention to two issues not addressed in the very important paper by Alice Dreger, Ellen Feder, and Anne Tamar-Mattis:

  • Heino Meyer-Bahlburg, one of the proponents of dexamethasone use, is also on the working groups for the DSM-5 and WPATH Standards of Care revisions, which pathologise gender variance in intersex people, and trans people. See our report, below.
  • Discussions within OII Australia over the weekend mean that we now believe that dex use does not occur in Australia, but amniocentesis testing for CAH is, however, known to have led to a very significant drop in live births of infants with CAH.

Additional information